NSW GOVERNMENT | Health

POISONS AND THERAPEUTIC GOODS REGULATION 2008

AUTHORITY

Authority to issue prescriptions for and supply dexamfetamine, lisdexamfetamine and methylphenidate

I, Bruce Battye, Acting Chief Pharmacist, a duly authorised delegate of the Secretary, NSW Health, make this instrument pursuant to clause 170 of the *Poisons and Therapeutic Goods Regulation 2008* (NSW) [the Regulation] for the purposes of clauses 84(2) and 98(2) of the Regulation. Pursuant to clause 171(1) of the Regulation, the authorisation is granted subject to conditions.

BRUCE BATTYE
Acting Chief Pharmacist
(Delegation Numbers PH380 & PH381)

Date: 31 OCT 2023

Authorisation to a class of persons to issue a prescription and supply without an authority under section 29 of the Poisons and Therapeutic Goods Act 1966

1 Authority reference number

CA2023

2 Authorisation

This authority authorises a medical practitioner in an Authorised Class of Persons to supply and issue a prescription for a specified Type A drug of addiction (namely dexamfetamine, lisdexamfetamine or methylphenidate) to a person for the purpose of treating the person for attention deficit hyperactivity disorder (ADHD) without an authority under section 29 of the *Poisons and Therapeutic Goods Act 1966* (the Act).

3 Definitions

In this instrument:

- *ADHD* means a diagnosis meeting the criteria in the:
  - *Diagnostic and Statistical Manual of Mental Disorders*, fifth edition (DSM-5) published by the American Psychiatric Association, or
  - *International Classification of Diseases,* 11th Revision (ICD-11) published by the World Health Organisation.
- *drug dependent person* has the same meaning as in the Act, section 27.

4 Authorised Class of Persons

Medical practitioners registered in the following fields of specialty practice within a specialty:

Specialty	Field of specialty practice
Paediatrics and child health	Any
Physician	Neurology
Psychiatry	N/A

5 Conditions

5.1 The medical practitioner in the Authorised Class of Persons must issue a prescription for dexamfetamine, lisdexamfetamine or methylphenidate only for the purpose of the treatment of a person for ADHD.

5.2 The medical practitioner in the Authorised Class of Persons must directly supply dexamfetamine, lisdexamfetamine or methylphenidate only for the purpose of testing the suitability of the person to undergo a course of medical treatment involving dexamfetamine, lisdexamfetamine or methylphenidate for the treatment of ADHD.

5.3 This authority does not authorise issue of a prescription for, or supply to, a person who is a drug dependent person.

5.4 This authority does not authorise issue of a prescription/s for, or supply to, a person above the following daily dose limits.

Drug	Daily dose limit
dexamfetamine	50 milligrams
lisdexamfetamine	70 milligrams
methylphenidate	108 milligrams

5.5 The medical practitioner in the Authorised Class of Persons must issue a prescription for or supply dexamfetamine, lisdexamfetamine or methylphenidate only within his/her lawful scope of practice, in accordance with all applicable standards, codes and guidelines, and within treatment protocols substantiated by scientific evidence and any approved product information.

6 Duration

This authority commences on 13 November 2023 and expires on 13 November 2025, or otherwise on a date that this authority is earlier cancelled.

NOTE: The medical practitioner in the Authorised Class of Persons must include the authority reference number "CA2023" on each prescription issued under this authority, as required under clause 80(1)(i) of the Regulation.